Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients

Myelofibrosis is a myeloproliferative neoplasm (MPN) which typically results in reduced length and quality of life due to systemic symptoms and blood count changes arising from fibrotic changes in the bone marrow. While the JAK2 inhibitor ruxolitinib provides some clinical benefit, there remains a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Pearson, Stella, Blance, Rognvald, Yan, Fei, Hsieh, Ya-Ching, Geary, Bethany, Amaral, Fabio M. R., Somervaille, Tim C. P., Kirschner, Kristina, Whetton, Anthony D., Pierce, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228771/
https://www.ncbi.nlm.nih.gov/pubmed/37253035
http://dx.doi.org/10.1371/journal.pone.0286412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228771/
https://www.ncbi.nlm.nih.gov/pubmed/37253035
http://dx.doi.org/10.1371/journal.pone.0286412

Ejemplares similares